OncoSec Medical Inc (ONCSQ)

[hschlauch]

Breakthrough Therapy designations have been bestowed on companies with fewer numbers. I don't see how any anti pd-1/pd-l1 company would not see value in extending use to an otherwise refractory population - right now, even with ctla-4 combination, they achieve no more than 22% complete remission in a metastatic melanoma SUBPOPULATION WITH BRAF WILD TYPE MUTATION. If ONCS is effective in turning refractory/ non-responding patients into responders, it would hypothetically more than double estimated peak revenues for the checkpoint inhibitor companies if they were to partner; that is a lot of incentive, and this "puny" phase 2 trial is a value creator in my book.